Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    21561347 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma
Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Capecitabine;   Drug: Oxaliplatin;   Drug: Irinotecan
2 Unknown  Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
3 Completed Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine;   Drug: nab-paclitaxel;   Drug: FOLFIRINOX;   Genetic: Immunohistochemistry (IHC) Analysis;   Drug: Metformin;   Drug: mFOLFIRI
4 Recruiting Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Conditions: Cancer;   Pancreatic Cancer
Interventions: Procedure: Tumour Biopsy;   Other: Serial Collection of Plasma, Serum and Urine Samples
5 Not yet recruiting Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
Condition: Pancreatic Adenocarcinoma
Intervention: Drug: Preoperative modified FOLFIRINOX and postoperative gemcitabine
6 Recruiting Alternative Dosing for CRLX101 Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: CRLX101;   Drug: Bevacizumab;   Drug: mFOLFOX6
7 Recruiting Intraoperative Radiation Therapy for Resectable Pancreas Cancer
Condition: Pancreas Cancer
Interventions: Radiation: 10 Gy Low-KV IORT;   Radiation: 15 Gy Low-KV IORT;   Radiation: 20 GY Low-KV IORT

Study has passed its completion date and status has not been verified in more than two years.